SEQUENOM Obtains Core Technology Patent in Europe
New Patent Significantly Expands Proprietary Position for MassARRAY(TM) Technology
SEQUENOM, Inc. announced that it has obtained a patent from the European Patent Office entitled "DNA Diagnostics Based On mass spectrometry." This core patent covers processes for detecting target nucleic acid sequences in a biological sample using mass spectrometry. The patent has been validated in 14 European countries, including Austria, Belgium, Denmark, Finland, France, Germany, Great Britain, Ireland, Italy, Netherlands, Portugal, Spain, Sweden and Switzerland, and relates to several patents previously issued in the United States.
"We are pleased to obtain this key patent from the European Patent Office," Toni Schuh, Ph.D., SEQUENOM's President and Chief Executive Officer. "Our MassARRAY technology is already recognized as a reference standard in high-performance genetic analysis. This patent secures the intellectual property position for our technology in Europe, one of our largest and most vital markets."
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!
Topic World Mass Spectrometry
Mass spectrometry enables us to detect and identify molecules and reveal their structure. Whether in chemistry, biochemistry or forensics - mass spectrometry opens up unexpected insights into the composition of our world. Immerse yourself in the fascinating world of mass spectrometry!